Adicet Bio to Present at the American College of Rheumatology (ACR) Convergence 2024

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced acceptance of an oral presentation at the upcoming American College of Rheumatology (ACR) Convergence 2024 meeting, taking place November 14-19, 2024, in Washington, D.C.

Details of the oral presentation are as follows:

Title: ADI-001: An Allogeneic CD20-targeted γδ CAR T Cell Therapy with Potential for Improved Tissue Homing in Autoimmune Indications

Session Name: Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases II

Abstract Number: 1866169

Presenting Author: Monica Moreno, Ph.D.

Date and Time: November 19, 2024; 12:00 p.m. – 12:15 p.m. ET

About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.

Contacts

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  220.26
+2.31 (1.06%)
AAPL  260.19
+1.75 (0.68%)
AMD  234.66
+4.43 (1.92%)
BAC  51.71
+0.61 (1.19%)
GOOG  255.03
+2.50 (0.99%)
META  737.57
+4.16 (0.57%)
MSFT  522.79
+2.25 (0.43%)
NVDA  182.48
+2.20 (1.22%)
ORCL  281.33
+8.67 (3.18%)
TSLA  446.41
+7.44 (1.70%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.